ÂÜÀòÂÒÂ×

Dr. Max M. Søgaard holds a PhD in Biochemistry from University College London, UK, and a MSc in Molecular Biology from Aarhus University, Denmark.

He has 20 years of scientific research and process development experience, having served the last eight years at ExpreS2ion in roles ranging from Senior Scientist (Downstream) to Vice President, and prior to that 12 years of academic research focused on structural biology and molecular biophysics with an emphasis on infectious disease applications. Max heads internal R&D in order to extend ExpreS2ion’s unique capabilities and know-how in applying ExpreS2™ technology for customers and the company's own vaccine development.

Dr. Max M. Søgaard has been employed by the company since 2013 and was appointed Vice President in 2020.